Clinical use of HIV-1 resistance genotyping.: Predictive factors of poor virological evolution in salvage treatments

被引:0
|
作者
Riera-Jaume, Melcior
Peñaranda-Vera, Maria
Angels Ribas-Blanco, Ma.
Murillas-Angoiti, Javier
Campins, Antoni
Salas-Aparicio, Ana
Leyes-García, María
Pareja-Bezares, Antonio
Pérez, José Luis
Villalonga-Pieras, Concepción
机构
[1] Hosp Univ Son Dureta, Unidad Enfermedades Infecciosas, Med Interna Serv, Palma de Mallorca 07014, Spain
[2] Hosp Son Llatzer, Serv Med Prevent & Epidemiol, Palma de Mallorca, Spain
[3] Hosp Son Dureta, Microbiol Serv, Palma de Mallorca, Spain
来源
关键词
antiretroviral treatment; salvage treatment; HIV infection; antiviral drug resistance; antiviral sensitivity testing;
D O I
10.1016/S0213-005X(06)73767-3
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
OBJECTIVES. To describe the use of genotype resistance testing (GRT) for virological failure in clinical practice, and the long-term clinical and virological evolution in patients for whom it is requested. To identify the predictive factors of virological failure in patients with antiretroviral (ARV) salvage therapy. METHODS. Observational study in HIV-infected patients for whom GRT was requested for virological failure (VF) in the period of 1 October 1999 to 31 December 2001. Logistic regression analysis was used to determine the predictive factors of virological progression. RESULTS. Over the period studied, 196 patients required GRT for VF (15%) among those monitored in specific units. GRT was mainly requested for patients who had been extensively pretreated for a mean of 5 years and with a median of 5 ARV combinations. Half the patients presented 3 or more mutations associated with thymidine analogs (TAMs), mutations associated with non-nucleoside analogs (NNRTIs), and 5 or more mutations associated with protease inhibitors (Pis). In 143 (74%) patients, the RTV regimen was changed on the basis of GRT results. In the intent-to-treat analysis, the percentage of patients with plasma VL < 400 cop/mL at 6,12 and 18 months was 41%,29% and 17%, respectively. In the on-treatment analysis, the results were 50%,48% and 46%, respectively. Mean CD4 lymphocyte increase was 59.74 and 94 cells/mm(3). The variables predicting virological failure (plasma VL > 400 cop/ml) at 12 months were plasma VL > 30,000 cop/mL (OR 6,1.8-19.5) and accumulation of 3 or more TAMs (OR 4.4, 1.3-15) at the start of ARV salvage therapy. CONCLUSION. Even though in clinical practice GRT is requested for patients with various treatment failures, when ART salvage treatment was started, plasma VL was undetectable and immunological response persisted in 40% of patients followed-up for 18 months. The factors best predicting virological evolution were VL and the number of baseline TAMs.
引用
收藏
页码:225 / 231
页数:7
相关论文
共 50 条
  • [1] Predictive factors of virological success to salvage regimens containing protease inhibitors in HIV-1 infected children
    Beatriz Larru
    Carmen de Mendoza
    José Ma Bellón
    Ma Isabel de José
    Ma José Mellado
    Vincent Soriano
    Ma Angeles Muñoz-Fernandez
    José T Ramos
    BMC Infectious Diseases, 7
  • [2] CLINICAL AND VIROLOGICAL FACTORS INFLUENCING TRANSMISSION OF HIV-1 BY TRANSFUSION
    BUSCH, MP
    TRANSFUSION, 1992, 32 (08) : S56 - S56
  • [3] Evaluation of an affordable HIV-1 virological failure assay and antiretroviral drug resistance genotyping protocol
    Bronze, M.
    Aitken, S. C.
    Wallis, C. L.
    Steegen, K.
    Stuyver, L. J.
    de Wit, T. F. Rinke
    Stevens, W.
    JOURNAL OF VIROLOGICAL METHODS, 2013, 194 (1-2) : 300 - 307
  • [4] HIV-1 drug resistance genotyping - A review of clinical and economic issues
    Chaix-Couturier, C
    Holtzer, C
    Phillips, KA
    Durand-Zaleski, I
    Stansell, J
    PHARMACOECONOMICS, 2000, 18 (05) : 425 - 433
  • [5] Algorithm evolution for drug resistance prediction: comparison of systems for HIV-1 genotyping
    Wagner, Sarah
    Kurz, Mario
    Klimkait, Thomas
    ANTIVIRAL THERAPY, 2015, 20 (06) : 661 - 665
  • [6] Typability of HIV-1 specimens received for HIV-1 genotyping for drug resistance in a clinical reference laboratory.
    Hamdan, H
    Cohen, M
    Green, B
    LeBault, J
    Duong, D
    Kagan, R
    Fenwick, R
    Lewinski, M
    CLINICAL CHEMISTRY, 1998, 44 (11) : 2393 - 2393
  • [7] Virological and immunological effects of salvage therapy following treatment interruption and a shift in HIV-1 resistance genotype
    Izopet, J
    Souyris, C
    Sandres-Sauné, K
    Puissant, B
    Obadia, M
    Pasquier, C
    Puel, J
    Blancher, A
    Massip, P
    JOURNAL OF MEDICAL VIROLOGY, 2002, 68 (03) : 305 - 310
  • [8] Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection
    Moyle, GJ
    Wildfire, A
    Mandalia, S
    Mayer, H
    Goodrich, J
    Whitcomb, J
    Gazzard, BG
    JOURNAL OF INFECTIOUS DISEASES, 2005, 191 (06): : 866 - 872
  • [9] The use of probe arrays for HIV-1 resistance genotyping in a reference laboratory setting.
    Alcorn, T
    Johnston, DM
    CLINICAL CHEMISTRY, 1999, 45 (06) : S13 - S13
  • [10] Extensive HIV-1 antiretroviral drug class resistance is associated with inferior virological and clinical outcomes
    Napravnik, S.
    Keys, J.
    Stalzer, B.
    Eron, J. J.
    ANTIVIRAL THERAPY, 2007, 12 : S68 - S68